{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:24:04Z","timestamp":1788175444985,"version":"build-2803163510"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejpb.2026.115207","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:45:42Z","timestamp":1786491942000},"page":"115207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design and development of inhalable cefepime dry powder targeting P. aeruginosa infections"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0569-1763","authenticated-orcid":false,"given":"Prodip Kumar","family":"Baral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhra","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5750-7505","authenticated-orcid":false,"given":"Daniel","family":"Pletzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0823-8147","authenticated-orcid":false,"given":"Shyamal C.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115207_b0005","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s40265-021-01635-6","article-title":"The epidemiology and pathogenesis and treatment of P. aeruginosa infections: an update","volume":"81","author":"Reynolds","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejpb.2026.115207_b0010","doi-asserted-by":"crossref","unstructured":"P.K. Baral, J. Dummer, D. Pletzer, S.C. Das, Inhaled Antibiotic and Biologic Formulations Targeting P. aeruginosa, Pharmaceutics 2026, Vol. 18, 18 (2026) 162. https:\/\/doi.org\/10.3390\/pharmaceutics18020162.","DOI":"10.3390\/pharmaceutics18020162"},{"key":"10.1016\/j.ejpb.2026.115207_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12890-016-0339-5","article-title":"Cystic fibrosis lung environment and P. aeruginosa infection","volume":"16","author":"Bhagirath","year":"2016","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.ejpb.2026.115207_b0020","unstructured":"World Health Organization, WHO updates list of drug-resistant bacteria most threatening to human health, Https:\/\/Www.Who.Int\/News\/Item\/17-05-2024-Who-Updates-List-of-Drug-Resistant-Bacteria-Most-Threatening-to-Human-Health (2024)."},{"key":"10.1016\/j.ejpb.2026.115207_b0025","first-page":"277","article-title":"The antibiotic resistance crisis: part 1: causes and threats","volume":"40","author":"Ventola","year":"2015","journal-title":"Pharmacy and Therapeutics"},{"key":"10.1016\/j.ejpb.2026.115207_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/ice.2019.296","article-title":"Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015\u20132017","volume":"41","author":"Weiner-Lastinger","year":"2020","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"10.1016\/j.ejpb.2026.115207_b0035","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/jac\/dkac122","article-title":"Susceptibility profiles and resistance genomics of P. aeruginosa isolates from European ICUs participating in the ASPIRE-ICU trial","volume":"77","author":"Torrens","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2026.115207_b0040","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1165\/rcmb.2017-0321TR","article-title":"P. aeruginosa biofilms: host response and clinical implications in lung infections","volume":"58","author":"Maurice","year":"2018","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejpb.2026.115207_b0045","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.4014\/jmb.1611.11056","article-title":"P. aeruginosa biofilm, a programmed bacterial life for fitness","volume":"27","author":"Lee","year":"2017","journal-title":"J. Microbiol. Biotechnol."},{"key":"10.1016\/j.ejpb.2026.115207_b0050","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3390\/pathogens11030300","article-title":"Pathogenesis of the P. aeruginosa biofilm: a review","volume":"11","author":"Tuon","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.ejpb.2026.115207_b0055","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1128\/AAC.00099-07","article-title":"Pulmonary versus systemic delivery of antibiotics: comparison of vancomycin dispositions in the isolated rat lung","volume":"51","author":"de Jes\u00fas Valle","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2026.115207_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107661","article-title":"Inhaled antibiotics: a promising drug delivery strategies for efficient treatment of lower respiratory tract infections (LRTIs) associated with antibiotic resistant biofilm-dwelling and intracellular bacterial pathogens","volume":"227","author":"Islam","year":"2024","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejpb.2026.115207_b0065","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/17425247.2016.1224846","article-title":"Dry powder inhalation: past, present and future","volume":"14","author":"de Boer","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2026.115207_b0070","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.3390\/jcm12103577","article-title":"Efficacy and safety of dry powder antibiotics: a narrative review","volume":"12","author":"de la Rosa-Carrillo","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejpb.2026.115207_b0075","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1513\/AnnalsATS.201311-395FR","article-title":"Inhaled antibiotics for lower airway infections","volume":"11","author":"Quon","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.ejpb.2026.115207_b0080","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40265-014-0181-0","article-title":"Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic P. aeruginosa infection in patients with cystic fibrosis","volume":"74","author":"Conole","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ejpb.2026.115207_b0085","doi-asserted-by":"crossref","unstructured":"A. Elfadadny, R.F. Ragab, M. AlHarbi, F. Badshah, E. Ib\u00e1\u00f1ez-Arancibia, A. Farag, A.O. Hendawy, P.R. De los R\u00edos-Escalante, M. Aboubakr, S.A. Zakai, Antimicrobial resistance of P. aeruginosa: navigating clinical impacts, current resistance trends, and innovations in breaking therapies, Front. Microbiol. 15 (2024) 1374466.","DOI":"10.3389\/fmicb.2024.1374466"},{"key":"10.1016\/j.ejpb.2026.115207_b0090","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(07)70109-3","article-title":"Efficacy and safety of cefepime: a systematic review and meta-analysis","volume":"7","author":"Yahav","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejpb.2026.115207_b0095","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1128\/AAC.01183-09","article-title":"Clinical pharmacodynamics of cefepime in patients infected with P. aeruginosa","volume":"54","author":"Crandon","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2026.115207_b0100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/17425255.2024.2427310","article-title":"Cefepime\/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation","volume":"21","author":"Darlow","year":"2025","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejpb.2026.115207_b0105","unstructured":"The European Committee on Antimicrobial Susceptibility Testing, Breakpoint tables for interpretation of MICs and zone diameters. , Version 15.0 (2025)."},{"key":"10.1016\/j.ejpb.2026.115207_b0110","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1128\/AAC.35.11.2312","article-title":"Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and P. aeruginosa SC8329","volume":"35","author":"Pucci","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2026.115207_b0115","first-page":"1","author":"O\u2019Connor","year":"2024","journal-title":"Cefepime, XPharm: the Comprehensive Pharmacology Reference"},{"key":"10.1016\/j.ejpb.2026.115207_b0120","article-title":"A review of recently discovered mechanisms of cephalosporin resistance in P. aeruginosa","volume":"66","author":"Boys","year":"2025","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"Suppl 2","key":"10.1016\/j.ejpb.2026.115207_b0125","first-page":"31","article-title":"Antibacterial in vitro activity of fourth generation cephalosporins","volume":"8","author":"Hancock","year":"1996","journal-title":"J. Chemother."},{"key":"10.1016\/j.ejpb.2026.115207_b0130","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1128\/AAC.34.2.337","article-title":"Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents","volume":"34","author":"Nikaido","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2026.115207_b0135","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1128\/AAC.01410-08","article-title":"Extended-spectrum cephalosporinases in P. aeruginosa","volume":"53","author":"Rodr\u00edguez-Mart\u00ednez","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2026.115207_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.598498","article-title":"Cephalosporins interfere with quorum sensing and improve the ability of Caenorhabditis elegans to survive P. aeruginosa infection","volume":"12","author":"Kumar","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejpb.2026.115207_b0145","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1139\/cjm-2021-0229","article-title":"Effect of sub-inhibitory concentrations of cefepime on biofilm formation by P. aeruginosa","volume":"67","author":"Hagras","year":"2021","journal-title":"Can. J. Microbiol."},{"key":"10.1016\/j.ejpb.2026.115207_b0150","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1128\/AAC.47.6.1991-1994.2003","article-title":"Stability and antibacterial activity of cefepime during continuous infusion","volume":"47","author":"Sprauten","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2026.115207_b0155","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1345\/aph.1C313","article-title":"Stability of cefepime hydrochloride in AutoDose infusion system bags","volume":"37","author":"Trissel","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejpb.2026.115207_b0160","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/jac\/dkg134","article-title":"Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units","volume":"51","author":"Baririan","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2026.115207_b0165","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3390\/pr11020602","article-title":"The Stability Study of Cefepime Hydrochloride in Various Drug Combinations","volume":"11","author":"\u017bandarek","year":"2023","journal-title":"Processes"},{"key":"10.1016\/j.ejpb.2026.115207_b0170","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1128\/AAC.46.11.3654-3656.2002","article-title":"Pitfalls in cefepime titration from human plasma: plasma-and temperature-related drug degradation in vitro","volume":"46","author":"Bugnon","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2026.115207_b0175","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ejpb.2022.10.005","article-title":"Inhalable ceftazidime-roflumilast powder targeting infection and inflammation: Influence of incorporating roflumilast into ceftazidime-leucine co-amorphous formulation","volume":"180","author":"Adhikari","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115207_b0180","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijpharm.2012.01.026","article-title":"Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells","volume":"426","author":"Aquino","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115207_b0185","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/jamp.2017.1378","article-title":"Preparation and Characterization of Doripenem-Loaded Microparticles for Pulmonary delivery","volume":"31","author":"Yildiz-Pek\u00f6z","year":"2018","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ejpb.2026.115207_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121799","article-title":"Amino acids improve aerosolization and chemical stability of potential inhalable amorphous Spray-dried ceftazidime for P. aeruginosa lung infection","volume":"621","author":"Adhikari","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115207_b0195","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jcis.2004.04.023","article-title":"Investigation of surface properties of amino acids: polarity scale for amino acids as a means to predict surface exposed residues in films of proteins","volume":"277","author":"Maheshwari","year":"2004","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.ejpb.2026.115207_b0200","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1021\/acs.molpharmaceut.3c00756","article-title":"Improvement in inhalation properties of theophylline and levofloxacin by co-amorphization and enhancement in its stability by addition of amino acid as a third component","volume":"20","author":"Ueda","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115207_b0205","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1002\/jps.24599","article-title":"Interaction of formulation and device factors determine the in vitro performance of salbutamol sulphate dry powders for inhalation","volume":"104","author":"Muddle","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115207_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125892","article-title":"Preparation and in vitro characterization of inhalable cannabidiol dry powder for treating chronic obstructive pulmonary disease","volume":"682","author":"Komal","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115207_b0215","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071432","article-title":"Manipulation of Spray-Drying Conditions to develop an Inhalable Ivermectin Dry Powder","volume":"14","author":"Saha","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115207_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123411","article-title":"Inhalable dry powder containing remdesivir and disulfiram: Preparation and in vitro characterization","volume":"645","author":"Saha","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115207_b0225","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3390\/pharmaceutics12080715","article-title":"Co-amorphization of kanamycin with amino acids improves aerosolization","volume":"12","author":"Adhikari","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115207_b0230","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17091120","article-title":"Influence of Different Amino Acids on the Aerosolization, Stability and Cytotoxicity of Spray-Dried Cannabidiol Dry Powder for Inhalation","volume":"17","author":"Komal","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115207_b0235","first-page":"301","article-title":"Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing)","volume":"16","author":"Marple","year":"2003","journal-title":"Part II: Archival Calibration, Journal of Aerosol Medicine"},{"key":"10.1016\/j.ejpb.2026.115207_b0240","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.xphs.2016.02.007","article-title":"Tailored antibiotic combination powders for inhaled rotational antibiotic therapy","volume":"105","author":"Lee","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115207_b0245","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijpharm.2017.06.004","article-title":"Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis","volume":"528","author":"Momin","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115207_b0250","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1128\/jb.140.3.902-910.1979","article-title":"Outer membrane of P. aeruginosa: heat- 2-mercaptoethanol-modifiable proteins","volume":"140","author":"Hancock","year":"1979","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.ejpb.2026.115207_b0255","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1073\/pnas.0304622101","article-title":"The broad host range pathogen P. aeruginosa strain PA14 carries two pathogenicity islands harboring plant and animal virulence genes","volume":"101","author":"He","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejpb.2026.115207_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2023.12.010","article-title":"Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections","volume":"195","author":"Saha","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115207_b0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002205","article-title":"Cellular arrangement impacts metabolic activity and antibiotic tolerance in P. aeruginosa biofilms","volume":"22","author":"Dayton","year":"2024","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ejpb.2026.115207_b0270","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/5673214","article-title":"Solid\u2010State FTIR Spectroscopic Study of two Binary Mixtures: Cefepime\u2010Metronidazole and Cefoperazone\u2010Sulbactam","volume":"2017","author":"Ali","year":"2017","journal-title":"J. Spectrosc."},{"key":"10.1016\/j.ejpb.2026.115207_b0275","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13568-023-01619-7","article-title":"Efficient green silver nanoparticles-antibiotic combinations against antibiotic-resistant bacteria","volume":"13","author":"Adil","year":"2023","journal-title":"AMB Express"},{"key":"10.1016\/j.ejpb.2026.115207_b0280","unstructured":"K. Grodowska, A. Parczewski, Organic solvents in the pharmaceutical industry, (2010)."},{"key":"10.1016\/j.ejpb.2026.115207_b0285","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.cogsc.2019.05.004","article-title":"Water\u2014the greenest solvent overall","volume":"18","author":"Zhou","year":"2019","journal-title":"Curr. Opin. Green Sustain. Chem."},{"key":"10.1016\/j.ejpb.2026.115207_b0290","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejps.2018.10.026","article-title":"Spray drying of pharmaceuticals and biopharmaceuticals: critical parameters and experimental process optimization approaches","volume":"127","author":"Ziaee","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115207_b0295","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0378-5173(97)00137-3","article-title":"Stability study of cefepime in different infusion solutions","volume":"154","author":"Rabouan-Guyon","year":"1997","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115207_b0300","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/bmc.3288","article-title":"A degradation study of cefepime hydrochloride in solutions under various stress conditions by TLC\u2013densitometry","volume":"29","author":"D\u0105browska","year":"2015","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.ejpb.2026.115207_b0305","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.addr.2015.12.010","article-title":"Spray drying formulation of amorphous solid dispersions","volume":"100","author":"Singh","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2026.115207_b0310","doi-asserted-by":"crossref","unstructured":"A. Gandi, D.K. Rajana, P. Saripilli, V. Dadi, Quality by design-driven RP-HPLC stability indicating method for concurrent estimation of enmetazobactam and cefepime in bulk and dosage form: a greenness and blueness approach, Journal of the Iranian Chemical Society 2026 23:5 23 (2026) 113-. https:\/\/doi.org\/10.1007\/S13738-026-03409-X.","DOI":"10.1007\/s13738-026-03409-x"},{"key":"10.1016\/j.ejpb.2026.115207_b0315","first-page":"31","article-title":"Alpha tocopherol loaded chitosan oleate nanoemulsions for wound healing","volume":"123","author":"Bonferoni","year":"2018","journal-title":"Evaluation on Cell Lines and Ex Vivo Human Biopsies, and Stabilization in Spray Dried Trojan Microparticles, European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115207_b0320","first-page":"1","article-title":"Specification of drug substances and products: Development and validation of analytical methods","author":"Riley","year":"2013","journal-title":"Specification of Drug Substances and Products: Development and Validation of Analytical Methods"},{"key":"10.1016\/j.ejpb.2026.115207_b0325","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1021\/acs.molpharmaceut.7b00690","article-title":"Excipient-free pulmonary delivery and macrophage targeting of clofazimine via air jet micronization","volume":"14","author":"Brunaugh","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115207_b0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.03.017","article-title":"Formulation strategy and use of excipients in pulmonary drug delivery","volume":"392","author":"Pilcer","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115207_b0335","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s11095-007-9475-1","article-title":"Pharmaceutical particle engineering via spray drying","volume":"25","author":"Vehring","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115207_b0340","doi-asserted-by":"crossref","unstructured":"K. Karimi, G. Katona, I. Cs\u00f3ka, R. Ambrus, Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride, J. Pharm. Biomed. Anal. 148 (2018) 73\u201379. https:\/\/doi.org\/K.Karimi,G.Katona,I.Cs\u00f3ka,R.Ambrus,Physicochemicalstabilityandaerosolizationperformanceofdrypowderinhalationsystemcontainingciprofloxacinhydrochloride,J.Pharm.Biomed.Anal.148(2018)73\u201379.","DOI":"10.1016\/j.jpba.2017.09.019"},{"key":"10.1016\/j.ejpb.2026.115207_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123949","article-title":"Co-spray dried inhalable composite powders of ciprofloxacin and alginate oligosaccharide as anti-biofilm therapy","volume":"654","author":"Zhang","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115207_b0350","first-page":"97","article-title":"How to Read and Interpret FTIR Spectroscope of Organic Material, Indonesian","volume":"4","author":"Nandiyanto","year":"2019","journal-title":"J. Sci. Technol."},{"key":"10.1016\/j.ejpb.2026.115207_b0355","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0378-5173(90)90221-O","article-title":"The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state","volume":"62","author":"Ahlneck","year":"1990","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115207_b0360","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12127-016-0210-7","article-title":"Rapid analysis of N-methylpyrrolidine in cefepime with thermal desorption ion mobility spectrometry","volume":"19","author":"Reynolds","year":"2016","journal-title":"Int. J. Ion Mobil. Spectrom."},{"key":"10.1016\/j.ejpb.2026.115207_b0365","doi-asserted-by":"crossref","unstructured":"R. Sanghvi, R. Narazaki, S.G. Machatha, S.H. Yalkowsky, Solubility Improvement of Drugs using N-Methyl Pyrrolidone, AAPS PharmSciTech 2008 9:2 9 (2008) 366\u2013376. https:\/\/doi.org\/10.1208\/s12249-008-9050-z.","DOI":"10.1208\/s12249-008-9050-z"},{"key":"10.1016\/j.ejpb.2026.115207_b0370","doi-asserted-by":"crossref","unstructured":"S.H. Yalkowsky, Y. He, P. Jain, Handbook of aqueous solubility data, CRC press, 2016.","DOI":"10.1201\/EBK1439802458"},{"key":"10.1016\/j.ejpb.2026.115207_b0375","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s11082-022-04118-4","article-title":"Theoretical study on spectral and optical properties of essential amino acids: a comparative study","volume":"54","author":"Lakhera","year":"2022","journal-title":"Opt. Quantum Electron."},{"key":"10.1016\/j.ejpb.2026.115207_b0380","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1023523","article-title":"P. aeruginosa reference strains PAO1 and PA14: a genomic, phenotypic, and therapeutic review","volume":"13","author":"Grace","year":"2022","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejpb.2026.115207_b0385","unstructured":"I. Kukavica-Ibrulj, A. Bragonzi, M. Paroni, C. Winstanley, F. Sanschagrin, G.A. O\u2019Toole, R.C. Levesque, In vivo growth of P. aeruginosa strains PAO1 and PA14 and the hypervirulent strain LESB58 in a rat model of chronic lung infection, (2008)."},{"key":"10.1016\/j.ejpb.2026.115207_b0390","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/17425247.2022.2089111","article-title":"An expert opinion on respiratory delivery of high dose powders for lung infections","volume":"19","author":"Adhikari","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2026.115207_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122042","article-title":"Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices","volume":"624","author":"Saha","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115207_b0400","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/0022-4804(80)90157-2","article-title":"Changes in lung water and capillary permeability following sepsis and fluid overload","volume":"28","author":"Hill","year":"1980","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.ejpb.2026.115207_b0405","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.969326","article-title":"Biofilm aggregates and the host airway-microbial interface","volume":"12","author":"Hall-Stoodley","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ejpb.2026.115207_b0410","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.tiv.2012.10.007","article-title":"In vivo\u2013in vitro comparison of acute respiratory tract toxicity using human 3D airway epithelial models and human A549 and murine 3T3 monolayer cell systems","volume":"27","author":"Sauer","year":"2013","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.ejpb.2026.115207_b0415","first-page":"275","article-title":"Safety assessment of excipients (SAFE) for orally inhaled drug products","volume":"37","author":"Metz","year":"2020","journal-title":"ALTEX-Alternatives to Animal Experimentation"},{"key":"10.1016\/j.ejpb.2026.115207_b0420","unstructured":"The European Committee on Antimicrobial Susceptibility Testing, Breakpoint tables for interpretation of MICs and zone diameters. Version 15.0, Https:\/\/Www.Eucast.Org. (2025)."},{"key":"10.1016\/j.ejpb.2026.115207_b0425","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pharmthera.2014.05.003","article-title":"Across the pulmonary epithelial barrier: Integration of physicochemical properties and human cell models to study pulmonary drug formulations","volume":"144","author":"Haghi","year":"2014","journal-title":"Pharmacol. Ther."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126002286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126002286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:13:06Z","timestamp":1788174786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126002286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":85,"alternative-id":["S0939641126002286"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115207","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and development of inhalable cefepime dry powder targeting P. aeruginosa infections","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115207"}}